Mesoblast (MESO) Stock: Buy, Sell, or Hold?
MESO - Mesoblast Limited American Depositary Shares
$14.32
-0.33 (-2.25%)
▼
5d:
-7.49%
30d:
-13.21%
90d:
-0.42%
HOLD
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Sep 04, 2026
0d
Get Alerted When MESO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: MESO shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: MESO shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: MESO is currently trading at $14.32, which is considered oversold relative to its 30-day fair value range of $14.81 to $16.95. From a valuation perspective, the stock is trading at a discount (Forward PE: -238.7) compared to its historical average (206.7). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, MESO is in a uptrend. The price is currently testing key support at $14.19. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MESO scores 66/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $37.00 (+158.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, MESO is in a uptrend. The price is currently testing key support at $14.19. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MESO scores 66/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $37.00 (+158.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$14.81 -
$16.95
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
95.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (66/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 158.4% below Wall St target ($37.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Bottoming setup, but lagging the sector by 29% over 20 days — wait for relative strength
- CAUTION: 5-day price weakness (-7.5%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$14.81 -
$16.95
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$14.19
Resistance Level
$16.03
Current Trend
Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-238.67
Wall Street Target
$37.00
(+158.4%)
Revenue Growth (YoY)
390.7%
Profit Margin
-47.8%
PE vs Historical
-238.7 vs 206.7
CHEAP
Share & Embed Analysis
Last updated: October 02, 2026 7:09 AM ET
Data refreshes hourly during market hours. Next update: 8:09 AM
Data refreshes hourly during market hours. Next update: 8:09 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MESO showing a specific setup today?
Insider Activity (6 Months)
3
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Gregory George
BUY
2324072 shares
2026-04-10
Gregory George
BUY
1586890 shares
2026-04-09
Gregory George
BUY
1981890 shares
2026-04-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$84 | 68 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$28 | 63 BUY |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$310 | 69 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 60 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
